{"entity":{"id":"trop2-expression","kind":"biomarker","name":"TROP2 expression","aka":["TROP2","TROP-2","Trop-2 expression","TACSTD2 expression","TROP2 QCS","TROP2 normalised membrane ratio"],"tldr":"TROP2 is on the surface of most breast and lung cancers. Sacituzumab govitecan and datopotamab deruxtecan are given without measuring it; a computational TROP2 score is being tested as a selector in lung cancer.","summary":"Sacituzumab govitecan (Trodelvy) is labelled for triple-negative and HR-positive HER2-negative breast cancer and urothelial cancer, datopotamab deruxtecan (Datroway) for HR-positive HER2-negative breast cancer and EGFR-mutant NSCLC, in both cases without a TROP2 test. The TROPION-Lung01 exploratory analysis introduced a quantitative continuous scoring (normalised membrane ratio) that separated responders in non-squamous NSCLC; it is being validated prospectively (TROPION-Lung12, NCT06564844 and other studies) and is not in any label.","asOf":"2026-09-23","links":[{"label":"TRODELVY prescribing information (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d"}],"tags":["biomarker","surface-antigen","no-threshold"],"related":["her2-low","nectin-4-expression"],"cancers":["tnbc","tnbc-metastatic","breast-hr-positive","urothelial","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["sacituzumab-govitecan","datopotamab-deruxtecan","sacituzumab-tirumotecan"],"companies":[],"institutions":[],"pathways":[],"terms":["ihc"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"target":"trop2","measurement":"ihc-score","scoringRule":{"text":"The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.","quote":"TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate","source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d","sourceLabel":"TRODELVY prescribing information (DailyMed)"},"thresholds":[],"tests":[],"assays":[],"companionDiagnostics":[],"forPatient":"You will not be tested for TROP2 before sacituzumab govitecan or datopotamab deruxtecan; the labels do not require it because nearly all eligible cancers express it. A computerised TROP2 score is under study in lung cancer and may become a selection test later."},"route":"/biomarkers/trop2-expression/","neighbours":{"term":[{"id":"her2-low","kind":"term","name":"HER2-low and HER2-ultralow","route":"/terms/her2-low/"},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"}],"biomarker":[{"id":"ceacam5-expression","kind":"biomarker","name":"CEACAM5 expression","route":"/biomarkers/ceacam5-expression/"},{"id":"nectin-4-expression","kind":"biomarker","name":"Nectin-4 expression","route":"/biomarkers/nectin-4-expression/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}]}}